Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Anti-tau antibody to inhibit the spread of pathological tau. Phase 1 SAD in healthy volunteers completed (acceptable safety/tolerability/immunogenicity); Phase 1 MAD in early AD patients initiated Feb 2025.
Status note Tau-silencing gene therapy: intravenously delivered TRACER capsid containing vectorized siRNA targeting tau mRNA. GLP toxicology study expected Q1 2026; IND submission anticipated Q2 2026 (after Q1 2026 Type C FDA communication); clinical trial initiation and dosing expected Q4 2026.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.